The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

This study was performed to evaluate the effects of vitamin D and omega-3 fatty acids co-supplementation on glucose metabolism and lipid concentrations in gestational diabetes (GDM) patients.

Who Took Part

The study group was 140 patients.

By PubMed's age tags, the people studied were adults, women only.

This randomized double-blind placebo-controlled clinical trial was done among 140 GDM patients.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes, Gestational, Dietary Supplements, Drug Interactions, Fatty Acids, Omega-3, Homeostasis and Lipids.

Author keywords: Gestational diabetes, Glycemic control, Lipid concentrations, Omega-3 fatty acid, Supplementation and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 140 patients.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Journal of clinical lipidology), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.